TrialCompass TCL
Back to results
Phase 1RecruitingPriority 4 · Lower priorityNCT06393738

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

ClinicalTrials.gov

Plain-language summary

This Phase 1 trial is testing ARV-393 and Glofitamab for people whose a type of T-cell lymphoma called AITL has come back or has not responded to previous treatment. The study starts with lower doses to find the safest effective dose before testing in more people. It is available at 8 US locations across multiple states.

Who can join (key eligibility)

  • Age 18 Years or older
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)
  • May require specific number of prior treatments

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

ARV-393 (DRUG): Oral daily dose of ARV-393 at a specified dose level | Glofitamab (DRUG): Glofitamab infusion per labelled prescribing information

Drugs / treatments
ARV-393, Glofitamab
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

NCT06393738

Phase: Phase 1 | Status: Recruiting | Priority: Lower

Plain-language summary

This Phase 1 trial is testing ARV-393 and Glofitamab for people whose a type of T-cell lymphoma called AITL has come back or has not responded to previous treatment. The study starts with lower doses to find the safest effective dose before testing in more people. It is available at 8 US locations across multiple states.

Who can join

  • Age 18 Years or older
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)
  • May require specific number of prior treatments

What's being tested

ARV-393 (DRUG): Oral daily dose of ARV-393 at a specified dose level | Glofitamab (DRUG): Glofitamab infusion per labelled prescribing information

Drugs / treatments: ARV-393, Glofitamab

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, open-label

Enrollment target: 255 patients

Primary endpoint: Incidence of Dose Limiting Toxicities During First 28 Days; Percentage of Participants With Adverse Events Characterized by Severity, Seriousness, and Relationship to Study Drug as a Measure of Safety and Tolerability; Number of Participants With Abnormal Vital Signs, Abnormal ECG Readings (QT Interval) and Abnormal Laboratory Parameters; Percentage of Participants With Grade 3 or Grade 4 Clinical Lab Abnormalities Using the Common Terminology Criteria for Adverse Events (CTCAE) With Scale From Grade 1 Grade 5. Higher Score Means Worse Outcome

Ages: 18 Years to —

Start date: 2024-09-05 | Est. completion: 2028-03

Locations

8 US sites · 17 total

Connecticut, Michigan, New Jersey, New York, Ohio, Tennessee, Texas

Contact

Arvinas Operations, Inc. | clinicaltrialsARV-393@arvinas.com | 475-345-0791

Sponsor: Arvinas Inc. (INDUSTRY)

Tags

AITL/TFH · Relapsed/Refractory

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT06393738

Prepared using TrialCompass (trialcompass.com) on June 19, 2026. For informational purposes only. Always discuss with your healthcare team.